ARS Pharmaceuticals, Inc. (SPRY)

5.89 -2.32% (-0.14)

Over 3Y: -14.6%

2026-08-28
Style
Area Line Line with markersneeds a shorter window Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

5 10 15
2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Operating Cash Flow: -19.1M Q3 '21 — Free Cash Flow: -19.2M Q3 '21 — Net Income: -22.7M Q4 '21 — Operating Cash Flow: 27.9M Q4 '21 — Net Income: 45.8M Q1 '22 — Revenue: 663K Q1 '22 — Operating Cash Flow: -6.9M Q1 '22 — Free Cash Flow: -6.9M Q1 '22 — Net Income: -7.2M Q2 '22 — Revenue: 464K Q2 '22 — Operating Cash Flow: -7M Q2 '22 — Free Cash Flow: -7M Q2 '22 — Net Income: -6.4M Q3 '22 — Revenue: 189K Q3 '22 — Operating Cash Flow: -5.7M Q3 '22 — Free Cash Flow: -5.7M Q3 '22 — Net Income: -6.6M Q4 '22 — Revenue: 0 Q4 '22 — Operating Cash Flow: -20.5M Q4 '22 — Free Cash Flow: -20.6M Q4 '22 — Net Income: -14.4M Q1 '23 — Revenue: 20K Q1 '23 — Operating Cash Flow: -12.4M Q1 '23 — Free Cash Flow: -12.6M Q1 '23 — Net Income: -15M Q2 '23 — Revenue: 10K Q2 '23 — Operating Cash Flow: -16.7M Q2 '23 — Free Cash Flow: -16.7M Q2 '23 — Net Income: -17.4M Q3 '23 — Revenue: 0 Q3 '23 — Operating Cash Flow: -12.8M Q3 '23 — Free Cash Flow: -12.8M Q3 '23 — Net Income: -14.9M Q4 '23 — Revenue: 0 Q4 '23 — Operating Cash Flow: -17.4M Q4 '23 — Net Income: -7.2M Q1 '24 — Revenue: 0 Q1 '24 — Operating Cash Flow: -6.7M Q1 '24 — Free Cash Flow: -6.8M Q1 '24 — Net Income: -10.3M Q2 '24 — Revenue: 500K Q2 '24 — Operating Cash Flow: -7.3M Q2 '24 — Free Cash Flow: -7.3M Q2 '24 — Net Income: -12.5M Q3 '24 — Revenue: 2.1M Q3 '24 — Operating Cash Flow: -14.5M Q3 '24 — Free Cash Flow: -14.6M Q3 '24 — Net Income: -19.1M Q4 '24 — Revenue: 86.6M Q4 '24 — Net Income: 49.9M Q1 '25 — Revenue: 8M Q1 '25 — Operating Cash Flow: -40.7M Q1 '25 — Free Cash Flow: -40.8M Q1 '25 — Net Income: -33.9M Q2 '25 — Revenue: 15.7M Q2 '25 — Operating Cash Flow: -39.6M Q2 '25 — Free Cash Flow: -39.6M Q2 '25 — Net Income: -44.9M Q3 '25 — Revenue: 32.5M Q3 '25 — Operating Cash Flow: -47M Q3 '25 — Free Cash Flow: -47.2M Q3 '25 — Net Income: -51.2M Q4 '25 — Revenue: 28.1M Q4 '25 — Operating Cash Flow: -43.5M Q4 '25 — Free Cash Flow: -43.5M Q4 '25 — Net Income: -41.3M Q1 '26 — Revenue: 22.7M Q1 '26 — Operating Cash Flow: -44.9M Q1 '26 — Free Cash Flow: -44.9M Q1 '26 — Net Income: -60.6M Q2 '26 — Revenue: 33.7M Q2 '26 — Operating Cash Flow: -60.9M Q2 '26 — Free Cash Flow: -60.9M Q2 '26 — Net Income: -62.3M -60M -30M 0 30M 60M 90M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 26.7%
OE margin -194.9%
Oper. margin -185.0%
Accruals -7.6%
EBITDA margin -183.6%
FCF margin -168.1%
OCF margin -168.0%
Profit margin -184.2%
ROA -86.3%
ROCE -114.7%
ROE -1721.8%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales 0.0046×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -88.2×
Cash / Debt 1.5×
Debt payback 0.0 yr
Quick ratio 3.0×
Cash runway 0.24 yr
Debt / Eq 7.7×
F-score 3.4 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.1
Sales CAGR 4Y +97.8%
Sales/sh Y/Y +8.1%
Sales Q/Q +114.2%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.